Press Releases Evoke Pharma, Inc.

Equities

EVOK

US30049G2030

Market Closed - Nasdaq Other stock markets 02:00:01 11/05/2024 am IST			5-day change	1st Jan Change
0.461 ^USD	-2.95%		-5.05%	-56.11%

09/05	Certain Options of Evoke Pharma, Inc. are subject to a Lock-Up Agreement Ending on 9-MAY-2024.	CI
09/05	Certain Common Stock of Evoke Pharma, Inc. are subject to a Lock-Up Agreement Ending on 9-MAY-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications	17/04	AQ
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer	22/03	AQ
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results	15/03	AQ
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024	08/03	AQ
Evoke Pharma Announces Closing of $7.5 Million Public Offering	14/02	AQ
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million	09/02	AQ
Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray	30/11	AQ
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent	27/11	AQ
Evoke Pharma : Failure to Satisfy Listing Rule - Form 8-K	23/11	PU
Evoke Pharma - United States Patent and Trademark Office Grants another Formulation Patent Covering GIMOTI	15/11	AQ
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI	14/11	AQ
Evoke Pharma Reports Third Quarter 2023 Financial Results	09/11	AQ
Evoke Pharma and EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide	01/11	AQ
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023	31/23/31	AQ
Evoke Pharma's Abstract Entitled 'Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients' to Be Presented at The American College of Gastroenterology 2023	19/23/19	AQ
Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting	18/23/18	AQ
Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®	14/23/14	AQ
Evoke Pharma Reports Second Quarter 2023 Financial Results	10/23/10	AQ
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society Meeting	08/23/08	AQ
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting	07/23/07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Evoke Pharma, Inc.

Equities

EVOK

US30049G2030

Press Releases

Filters